Company intelligence / Profile preview

United Immunity Co., Ltd.

Chuo-ku, Tokyo, Japanunitedimmunity.co.jp ↗

Ownership: Private
Development stage: Preclinical

Overview

Developing nanotechnology-based drug delivery systems that target myeloid cells to reprogram tumor-associated macrophages and activate T cells. Lead candidate UI-102 is advancing from preclinical to Phase 1 for treatment of immune-resistant cold solid tumors.

Therapeutic areas: PulmonologyMetabolic DisordersImmunologyOncologyInfectious Diseases
Modalities: Nanogelslipid nanoparticlesmRNAsiRNADNAsmall moleculespeptidesproteins
Industry: Biotech

Drug pipeline

3 assets

UI-102

2 more assets in the full pipeline.

Request access →

Partnerships

Xyphos Biosciences (Astellas subsidiary)AstraZeneca

Beyond the preview

Go deeper on United Immunity Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on United Immunity Co., Ltd..

Explore the full profile